Investigating Solriamfetol for Binge Eating Disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 trial evaluates the efficacy and safety of solriamfetol in treating adults with binge eating disorder (BED). Participants will be randomly assigned to receive either solriamfetol at doses of 150 mg or 300 mg, or a placebo, once daily for 12 weeks. The study aims to determine how well solriamfetol works in reducing binge eating episodes and improving overall symptoms associated with BED. Eligible participants must meet specific diagnostic criteria and provide informed consent before joining the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Primary diagnosis of BED according to DSM-5 criteria.
* Provides written informed consent to participate in the study before the conduct of any study procedures.
* Male or female, aged 18 to 55 inclusive.

Exclusion Criteria:

* Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
* Unable to comply with study procedures.
* Medically inappropriate for study participation in the opinion of the investigator.

Where it's running

• Clinical Research Site
  Encino, California, United States Recruiting
• Clinical Research Site
  Garden Grove, California, United States Recruiting
• Clinical Research Site
  Long Beach, California, United States Recruiting
• Clinical Research Site
  Mission Viejo, California, United States Recruiting
• Clinical Research Site
  Santa Ana, California, United States Recruiting
• Clinical Research Site
  Walnut Creek, California, United States Recruiting

Study contacts

• Study coordinator: Study Director
• Email: sol-bed-301@axsome.com
• Phone: 212-332-5061

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• E-diary vs Paper Diary in Binge Eating Disorder

  This study tests whether an electronic diary and a paper diary capture binge eating episodes in the same way for adults with binge eating disorder.

  Recruiting Lindner Center of HOPE · Mason, Ohio · NCT07715812

• Four CBT-E formats for Binge Eating Disorder in adults

  This trial tests four different psychotherapy formats to see which best reduces binge-eating episodes in adults with Binge Eating Disorder.

  Recruiting Herlev and Gentofte Hospital · Ballerup Municipality, Capital Region · NCT07698132

• Eating Disorder Dynamic Intervention

  A digital program is tested to help adults with eating disorders by sending real-time, personalized coping tips based on smartphone surveys and sensor data.

  Recruiting Trustees of Dartmouth College · Lebanon, New Hampshire · NCT07600671

• COR program for treating binge eating in Chilean adults

  This project will try an eight-week online COR program to help adults in Chile who have recurrent binge-eating episodes.

  Recruiting Universidad Catolica de Temuco · Temuco, La Araucanía · NCT07435974

• An AI chatbot to help teens and young adults with eating disorders manage anxiety about weight gain

  This project will test an AI-powered chatbot that delivers exposure-based exercises to help adolescents and young adults in a partial hospitalization program reduce anxiety about weight gain.

  Recruiting Milton S. Hershey Medical Center · Hershey, Pennsylvania · NCT07237607

• Digital cognitive-behavioral therapy plus mindfulness for binge eating

  This pilot will test whether a 16-session guided digital program combining CBT and mindfulness with coaching helps adults with binge eating disorder more than coached self-monitoring.

  Recruiting Yeshiva University · The Bronx, New York · NCT07212673

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.